Table of Contents Table of Contents
Previous Page  738 / 812 Next Page
Information
Show Menu
Previous Page 738 / 812 Next Page
Page Background

S734

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

Methods

MEDLINE, PsycINFO databases were searched for arti-

cles published between 2005–2015 containing the keywords

“gender dysphoria”, “gender-variant people” and “transgender

people”. Relevant policies, guidelines and legislations were also

reviewed.

Results

Transgender people still face major health inequalities

and discrimination. National statistics show that 80% have expe-

rienced harassment, 62% suffered discrimination at work or home

and 54% reported being denied access to NHS care due to lack of

cultural competency from staff. Guidelines, research, policies and

equality legislation have begun to be implemented to protect trans-

gender people from discrimination and accord rights.

Conclusions

Many areas need attention and improvement includ-

ing not only healthcare but also employment, education, housing

and media perception. Promotion of equality in the general popu-

lation with the aim of achieving cultural change and improvement

of cultural competency of health professionals is needed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2189

EV1205

Flibanserin: The first drug approved

for the treatment of hypoactive sexual

desire disorder in pre-menopausal

women

N. Couto

1 ,

, R. Ribeiro Silva

2

1

Centro Hospitalar Vila Nova de Gaia/Espinho, EPE, Psychiatry and

Mental Health, Braga, Portugal

2

Centro Hospitalar Vila Nova de Gaia/Espinho, EPE, Psychiatry and

Mental Health, Vila Nova de Gaia, Portugal

Corresponding author.

Introduction

Hypoactive sexual desire disorder (HSDD) is char-

acterized by persistent or recurrent deficiency or absence of sexual

fantasies and desire for sexual activity, causing marked biopsy-

chosocial dysfunction. The etiology of HSDD involves a wide range

of biological and psychosocial factors. One of the biological factors

is the balance between excitatory and inhibitory neurotransmitter

pathways that regulate the sexual response in the central nervous

system. Flibanserin is a compound discovered in 1995, agonist of

the 5-HT1A antagonist and the 5-HT2A receptors, which became

August 2015 in the first drug approved for the treatment of HSDD.

Objectives

Describe the main pharmacokinetic and pharmaco-

dynamic characteristics of flibanserin, as well as the results and

conclusions of the phase three clinical trials that led to its approval

by the US regulatory authority.

Aims

To understand the potential benefits and risks of the clinical

use of flibanserin.

Methods

Search online titles and abstracts related to flibanserin.

Results

Flibanserin is a multifunctional serotonin agent who is

both a serotonin 1A agonist and a serotonin 2A antagonist. Theoret-

ically, flibanserin improves sexual activity by increasing dopamine

and norepinephrine release as it reduces serotonin release in

brain circuits that mediate the symptoms of interest/female sex-

ual arousal. Flibanserin showed a statistically significant increase in

the number of improvements and satisfactory sexual events in sev-

eral other validated scales. The main side effects include dizziness,

sleepiness, nausea and (rarely) syncope.

Conclusions

Despite the efficacy of flibanserin not produce statis-

tically powerful results, although statistically significant, this may

be important for a particular woman’s profile, including those in

which other psychotherapeutic approaches have failed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2190

EV1206

Personality traits and personality

disorders in gender dysphoria

V. Deiana

1 ,

, E. Corda

1

, C. Bandecchi

1

, S. Pintore

1

, F. Pinna

1

,

R. Pusceddu

1

, A. Oppo

2

, S. Mariotti

2

, A. Argiolas

1

,

B. Carpiniello

1

1

University of Cagliari, Clinica Psichiatrica, Cagliari, Italy

2

AOU Cagliari, Unità Operativa di Endocrinologia, Monserrato, Italy

Corresponding author.

Investigations in the field of gender dysphoria (GD) have been

mostly related to psychiatric comorbidity and severe psychiatric

disorders, but have focused less on personality traits and personal-

ity disorders (PDs).

We aimed to assess personality and the presence of PDs in a sam-

ple of 25 persons with GD attending the Psychiatric Clinic or the

Department of Endocrinology of the University of Cagliari request-

ing sex reassignment therapy. They were assessed through the

Minnesota Multiphasic Personality Inventory-2 (MMPI-2) and the

Structured Clinical Interview for DSM-IV Axis II (SCID-II).

The sample consisted of 14 MtF and 11 FtM, with a mean age of

29.6

±

9.5. Overall, 39.1% of the sample met the criteria for at least

one PD, more frequently cluster-B PD (21.7%). MtF met a higher

number of SCID-II criteria than FtM, especially regarding histrionic

personality traits (

P

= 0.001). A total of 20 persons (9 MtF and 11

FtM) completed the MMPI-2. Mean T scores did not differ from the

general population, except for the Psychopathic Deviate (Pd) scale

(mean T = 66.2

±

11.2). The Masculinity-Femininity (Mf) scale was

slightly increased, and its score reduced after correction for per-

ceived sex (

P

= 0.037). MtF scored significantly higher at the Family

Problems (FAM) scale (

P

= 0.052) and lower at the Social Discomfort

(SOD) scale (

P

= 0.005) compared to FtM.

The high prevalence of PDs confirms that this kind of assessment in

GD is of great importance, as a key part of personalized treatment

plan tailoring. The high scores on the Pd scale suggest misidentifi-

cation with societal standards.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2191

EV1207

Body image and gender role perceived

in gender dysphoria: Cross-sex

hormone therapy effects

E. Corda

1

, C. Bandecchi

1

, V. Deiana

1 ,

, S. Pintore

1

, F. Pinna

1

,

R. Pusceddu

1

, A. Oppo

2

, S. Mariotti

2

, A. Argiolas

1

,

B. Carpiniello

1

1

University of Cagliari, Clinica Psichiatrica, Cagliari, Italy

2

AOU Cagliari, Unità Operativa di Endocrinologia, Monserrato, Italy

Corresponding author.

The gender dysphoria (GD) refers to the distress caused by the

incongruence between gender identity and biological sex. This

occurs, especially in pre-treatment cross-sex hormone therapy

(CHT), with a marked dissatisfaction with their body image.

The purpose of this study is to evaluate the role of perceived gender

in a total of 20 subjects (9 MtFs and 11 FtMs), presented for initia-

tion of CHT at the Psychiatric Clinic or Department of Endocrinology

of University Hospital of Cagliari and deemed appropriate to take

the transition path aimed at sex reassignment. On a subsample of

7 patients (2 MtFs and 5 FtMs) were then evaluated changes, in

terms of improving the acceptance of body image, at 2 months

after initiation of CHT, using the Minnesota Multiphasic Person-

ality Inventory-2 (MMPI-2) (focusing on MF, Gm and Gf scale), the

BemSex Role Inventory (BSRI), and the Body Uneasiness Test (BUT).

The MF scale shows a moderate elevation, which is reduced signif-

icantly as a result of correction for perceived gender rather than

biological sex. MtFs get higher scores on the Gf scale and lower